EUCTR2006-000562-36-IT进行中（未招募）不适用
''A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer'' - ALTTO
GlaxoSmithKline R&D Ltd.0 个研究点目标入组 8,000 人开始时间: 2007年7月30日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 8,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Age > o equal 18 years 2. Eastern Cooperative Oncology Group (ECOG) performance status < o equal 1 3. Non-metastatic operable primary invasive adenocarcinoma of the breast fulfilling the following: a. Histologically confirmed; b. Adequately excised (exceptions: patients who have 'non-resectable' deep margin invasion are eligible provided they have had or will receive radiotherapyencompassing the region concerned; patients with histologically documented infiltration of the skin (pT4) are eligible provided they have undergone or will receive radiotherapy encompassing the tumour bed); c. Axilla dissected; sentinel node sampling is allowed provided that axillary dissection follows confirmation of a positive sentinel node; sentinel node sampling alone is NOT acceptable after neoadjuvant chemotherapy (in patients receiving neoadjuvant chemotherapy lymph node status will be considered unknown, regardless of the results of post-chemotherapy axillary dissection); d. Axillary node positive patient OR node negative patient with a tumour greater than or equal to 1.0 cm in greatest diameter (> o equal T1c) according to TNM. 4. Known hormone receptor status (ER/PgR or ER alone) 5. Must have received at least four cycles of an approved anthracycline-based (neo-) adjuvant chemotherapy regimen. For design 1: Randomisation must be performed no longer than 12 weeks from day 1 of the last chemotherapy cycle after obtaining a post-chemotherapy LVEF > o uguale 50. Study treatment should start no more than 14 days after randomisation. For design 2: Randomisation must be performed no longer than 6 weeks from day 1 of the last anthracycline-containing chemotherapy cycle after obtaining a postanthracycline chemotherapy LVEF > o equal 50. Study treatment should start no more than 14 days after randomization and must be concurrent with paclitaxel 6. Baseline LVEF > o equal 50% measured by echocardiography or MUGA scan after completion of all anthracycline-based (neo-) adjuvant chemotherapy and prior to the targeted therapy(ies). 7. Over expression and/or amplification of HER2 in the invasive component of the primary tumour (in case of neoadjuvant treatment, tissue sample used for HER2 testing should be collected before neoadjuvant treatment starts), according to one of the following definitions and confirmed by central laboratory prior to randomisation: ? 3+ over expression by IHC (> 30% of invasive tumour cells); ? 2+ or 3+ (in 30% or less neoplastic cells) over expression by IHC AND in situ hybridization (FISH/CISH) test demonstrating HER2 gene amplification; ? HER2 gene amplification by FISH/CISH ( > 6 HER2 gene copies per nucleus, or a FISH ratio [HER2 gene copies to chromosome 17 signals] of > than 2.2.) Patients with a negative or equivocal overall result (FISH test ratio of < 2.2, < 6.0 HER2 gene copies per nucleus) and staining scores of 0,1+, 2+ or 3+ (in 30% or less neoplastic cells) by IHC are not eligible for participation in the trial. Equivocal local results may be submitted for a final determination by the central laboratory 8. Completion of all necessary baseline laboratory and radiological investigations. 9. Signed written informed consent (approved by an Independent Ethics Committee and obtained prior to any study specific screening procedures).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderl
排除标准
- •1. History of any prior (ipsi- and/or contralateral) invasive breast carcinoma; 2. Past or current history of malignant neoplasms, except for curatively treated: ? Basal and squamous cell carcinoma of the skin; ? Carcinoma in situ of the cervix 3. Any clinically staged T4 tumour, including inflammatory breast cancer; 4. Bilateral tumours; 5. Multifocal tumours; 6. Maximum cumulative dose of doxorubicin >360mg/m2 or maximum cumulative dose of epirubicin >720mg/m2 or any prior anthracyclines unrelated to the present breast cancer; 7. (Neo-) or adjuvant chemotherapy using peripheral stem cell or bone marrow stem cell support; 8. Any prior mediastinal irradiation except internal mammary node irradiation for the present breast cancer; 9. Patients with positive or suspicious internal mammary nodes identified by sentinel node technique which have not been irradiated or will not be irradiated, or patients with supraclavicular lymph node involvement (confirmed by fine needle aspirate or biopsy); 10. Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for breast cancer; 11. Concurrent anti-cancer treatment, except hormonal therapy; 12. Concurrent anti-cancer treatment in another investigational trial with hormone therapy or immunotherapy: 13. Serious cardiac illness or medical conditions including but not confined to: ? History of documented congestive heart failure (CHF) or systolic dysfunction (LVEF <50%); ? High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block, supraventricular arrhythmias which are not adequately rate-controlled); ? Angina pectoris requiring antianginal medication; ? Clinically significant valvular heart disease; ? Evidence of transmural infarction on ECG;Poorly controlled hypertension (e.g. systolic >180mm Hg or diastolic >100mm Hg); 14. Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness; 15. Any of the following abnormal laboratory tests immediately prior to randomisation: ? serum total bilirubin >2.0 x upper limit of normal (ULN); ? alanine amino transferase (ALAT) or aspartate amino transferase (ASAT) >2.5 x ULN; ? alkaline phosphatase (ALP) > 2.5 x ULN; ? serum creatinine >2.0 x ULN; ? total white blood cell count (WBC) <2.5 x 109/L; ? absolute neutrophil count <1.5 x 109/L; ? platelets <100 x 109/L. 16. Unresolved or unstable serious adverse events from prior adjuvant chemotherapy or radiotherapy; 17. Malabsorption syndrome, any disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, or persons unable to swallow oral medication. Subjects with ulcerative colitis are also excluded; 18. Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test - urine or serum - within 7 days prior to randomisation); 19. Women of childbearing potential and male participants with partners of child bearing potential, including women whose last menstrual period was <1 year ago (unless surgically sterile) who are unable or unwilling to use adequate contraceptive measures during study treatment (adequate contraceptive measures: intra-uterine device, barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not indicated in this patient population); 20. Concomitant use of CYP3A4 inhibitors o
研究者
相似试验
招募中
2 期
An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS - PURO - AB 23/09bladder cancerC67Malignant neoplasm of bladderDRKS00003516GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH124
进行中（未招募）
不适用
An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS - PUROEUCTR2009-015119-42-DEGMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
进行中（未招募）
1 期
An open-label, multicentre, randomised phase II study of pazopanib in combination with pemetrexed in first-line treatment of subjects with predominantly non-squamous cell stage IIIBwet/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1 Level: LLT Classification code 10029521 Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-FRGlaxoSmithKline R&D Limited
进行中（未招募）
不适用
An open-label, multicentre, randomised phase II study of pazopanib in combination with pemetrexed in first-line treatment of subjects with predominantly non-squamous cell stage IIIBwet/IV non-small cell lung cancerHistologically- or cytologically-confirmed diagnosis of predominantly non-squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLCMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-002144-42-GBGlaxoSmithKline R&D Limited150
进行中（未招募）
不适用
An open-label, multicentre, randomised phase II study of pazopanib in combination with pemetrexed in first-line treatment of subjects with predominantly non-squamous cell stage IIIBwet/IV non-small cell lung cancer - NDsubjects with predominantly non-squamous cell stage IIIBwet/IV non-small cell lung cancerMedDRA version: 9.1Level: HLGTClassification code 10029107Term: Respiratory tract neoplasmsEUCTR2008-002144-42-ITGLAXOSMITHKLINE R&D LIMITED150